<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02963493</url>
  </required_header>
  <id_info>
    <org_study_id>OP-106</org_study_id>
    <nct_id>NCT02963493</nct_id>
  </id_info>
  <brief_title>A Study of Melflufen in Combination With Dexamethasone in Relapsed Refractory Multiple Myeloma Patients</brief_title>
  <acronym>HORIZON</acronym>
  <official_title>A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination With Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory to Pomalidomide and/or Daratumumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oncopeptides AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Precision Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oncopeptides AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate melflufen in combination with dexamethasone in the treatment of
      relapsed refractory multiple myeloma in adult patients with disease refractory to
      pomalidomide and/or daratumumab. All patients in the study will be treated with melflufen on
      Day 1 and dexamethasone on Days 1, 8, 15 and 22 of each 28-day cycle.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Melflufen is designed for targeted delivery of alkylating moieties to tumor cells. In
      contrast to other alkylating agents that are hydrophilic, the lipophilicity of melflufen
      leads to rapid and extensive distribution into tissues and cells. Inside cells, melflufen may
      directly bind DNA or is readily metabolized by intracellular peptidases into the well-known
      antitumor compound melphalan, or by esterases into des-ethylmelflufen, which also has
      alkylating properties. Due to the high activity of peptidases and esterases in human tumor
      cells, the formation of melflufen's metabolites is rapid in these cells with subsequent
      inflow of more melflufen. Since des-ethylmelflufen and melphalan are relatively hydrophilic,
      there is a possibility for intracellular trapping of these alkylators.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>At completion of treatment for all patients, approximately 2 years.</time_frame>
    <description>The overall response rate (ORR) will be estimated as the proportion of patients in each group who achieve sCR, CR, VGPR, or PR as their best response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>At time of progression, or, if no progression, 24 months after completion of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>At time of progression, or, if no progression, 24 months after completion of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>At time of death, or, if no death, 24 months after completion of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>melflufen + dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Melflufen 40 mg Day 1 and dexamethasone 40 mg (reduced dose for patients 75 years or older) on Days 1, 8, 15 and 22 of each 28-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melflufen</intervention_name>
    <arm_group_label>melflufen + dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>melflufen + dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, age 18 years or older

          -  A prior diagnosis of multiple myeloma with documented disease progression

          -  Measurable disease based on either of a) serum monoclonal protein by protein
             electrophoresis (SPEP), b) monoclonal protein in the urine on 24-hour urine
             electrophoresis (UPEP), and/or c) serum immunoglobulin free light chain combined with
             abnormal serum immunoglobulin kappa to lambda free light chain ratio

          -  A minimum of 2 prior lines of therapy including an IMiD and a PI and is refractory to
             pomalidomide and/or daratumumab

          -  Life expectancy of ≥ 6 months

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

          -  Female of child bearing potential (FCBP) and non-vasectomized male agree to practice
             appropriate methods of birth control

          -  Ability to understand the purpose and risks of the study and provide signed and dated
             informed consent and authorization to use protected health information

          -  12-lead ECG with QTc interval within defined limit

          -  Acceptable laboratory results during screening and prior to first study drug
             administration of the following parameters: absolute neutrophil count (ANC), platelet
             count, hemoglobin, total bilirubin, aspartate transaminase (AST/SGOT) and alanine
             transaminase (ALT/SGPT), renal function based on estimated creatinine clearance

          -  Must have, or accept to have, an acceptable central catheter for infusion of melflufen

        Exclusion Criteria:

          -  Evidence of mucosal or internal bleeding and/or is platelet transfusion refractory

          -  Any medical conditions that, in the Investigator's opinion, would impose excessive
             risk to the patient or would adversely affect his/her participating in this study

          -  Known active infection requiring parenteral or oral anti-infective treatment within
             defined period

          -  Primary refractory disease

          -  Other malignancy diagnosed or requiring treatment within the defined period with
             specific exceptions

          -  Pregnant or breast-feeding females

          -  Serious psychiatric illness, active alcoholism, or drug addiction that may hinder or
             confuse compliance or follow-up evaluation

          -  Known HIV or active hepatitis B or C viral infection

          -  Concurrent symptomatic amyloidosis or plasma cell leukemia

          -  POEMS syndrome [plasma cell dyscrasia with polyneuropathy, organomegaly,
             endocrinopathy, monoclonal protein (M-protein) and skin changes]

          -  Previous cytotoxic therapies, including cytotoxic investigational agents, for multiple
             myeloma within defined values prior to start of study treatment

          -  Residual side effects to previous therapy over specific grade prior to initiation of
             therapy

          -  Prior autologous or allogeneic stem cell transplant within defined period of
             initiation of therapy

          -  Prior allogeneic stem cell transplant with active graft-versus-host- disease (GVHD).

          -  Prior major surgical procedure or radiation therapy within specified period of the
             first dose of study treatment (with defined exception).

          -  Known intolerance to steroid therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eva Nordstrom, PhD</last_name>
    <phone>+46 706340211</phone>
    <email>eva.nordstrom@oncopetides.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jakob Lindberg, MLic, BA</last_name>
    <phone>+46 705695471</phone>
    <email>jakob.lindberg@oncopeptides.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>trials@oncopeptides.se</email>
    </contact>
    <investigator>
      <last_name>Jan Moreb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>RUSH</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>trials@oncopeptides.se</email>
    </contact>
    <investigator>
      <last_name>Agne Paner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>trials@oncopeptides.se</email>
    </contact>
    <investigator>
      <last_name>Paul Richardson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>trials@oncopeptides.se</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Zonder</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hudson Valley Hematology Oncology</name>
      <address>
        <city>Hawthorne</city>
        <state>New York</state>
        <zip>10532</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>trials@oncopeptides.se</email>
    </contact>
    <investigator>
      <last_name>Amitabha Mazumder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>trials@oncopeptides.se</email>
    </contact>
    <investigator>
      <last_name>Hani Hassoun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Research Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>trials@oncopeptides.se</email>
    </contact>
    <investigator>
      <last_name>Nashat Gabrail, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>trials@oncoppetides.se</email>
    </contact>
    <investigator>
      <last_name>Christopher Maisel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Scott and White Memorial Hospital</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>trials@oncopeptides.se</email>
    </contact>
    <investigator>
      <last_name>Kathleen Halka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universita di Bolognia</name>
      <address>
        <city>Bologna</city>
        <zip>40126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>trials@oncopeptides.se</email>
    </contact>
    <investigator>
      <last_name>Michele Cavo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Turin Hospital Myeloma Unit</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>trials@oncopeptides.se</email>
    </contact>
    <investigator>
      <last_name>Alessandra Larocca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>trials@oncopeptides.se</email>
    </contact>
    <investigator>
      <last_name>Joan Bladé Creixenti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Català d'Oncología (ICO) Badalona</name>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>trials@oncopeptides.se</email>
    </contact>
    <investigator>
      <last_name>Albert Oriol Rocafiguera</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>trials@oncopeptides.se</email>
    </contact>
    <investigator>
      <last_name>Adrián Alegre Amor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>trials@oncopeptides.se</email>
    </contact>
    <investigator>
      <last_name>Paula Rodríguez Otero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>trials@oncopeptides.se</email>
    </contact>
    <investigator>
      <last_name>Maria Victoria Mateos Manteca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2016</study_first_submitted>
  <study_first_submitted_qc>November 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2016</study_first_posted>
  <last_update_submitted>November 15, 2017</last_update_submitted>
  <last_update_submitted_qc>November 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>relapsed refractory multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

